348 related articles for article (PubMed ID: 36493578)
1. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.
Caliman E; Fancelli S; Petroni G; Gatta Michelet MR; Cosso F; Ottanelli C; Mazzoni F; Voltolini L; Pillozzi S; Antonuzzo L
Lung Cancer; 2023 Jan; 175():88-100. PubMed ID: 36493578
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
Pavan A; Attili I; Pasello G; Guarneri V; Conte PF; Bonanno L
J Immunother Cancer; 2019 Aug; 7(1):205. PubMed ID: 31383005
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
Zhu L; Qin J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):22. PubMed ID: 38245636
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
5. Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Remon J; Aldea M; Besse B; Planchard D; Reck M; Giaccone G; Soria JC
Ann Oncol; 2021 Jun; 32(6):698-709. PubMed ID: 33737119
[TBL] [Abstract][Full Text] [Related]
6. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Tian Y; Zhai X; Han A; Zhu H; Yu J
J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167
[TBL] [Abstract][Full Text] [Related]
7. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Lorenzi M; Resi MV; Bonanno L; Frega S; Dal Maso A; Ferro A; Guarneri V; Pasello G
Front Immunol; 2024; 15():1308109. PubMed ID: 38348046
[TBL] [Abstract][Full Text] [Related]
8. Potential subtype-specific therapeutic approaches in small cell lung cancer.
Horvath L; Lang C; Boettiger K; Aigner C; Dome B; Megyesfalvi Z
Curr Opin Oncol; 2024 Jan; 36(1):51-56. PubMed ID: 37865844
[TBL] [Abstract][Full Text] [Related]
9. A new hope: the immunotherapy in small cell lung cancer.
Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y
Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for small cell lung cancer: established applications and novel approaches.
Scott SC; Hann CL
Clin Adv Hematol Oncol; 2021 Oct; 19(10):654-663. PubMed ID: 34637432
[TBL] [Abstract][Full Text] [Related]
11. The role of immunotherapy in small cell lung cancer.
Calles A; Aguado G; Sandoval C; Álvarez R
Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
[TBL] [Abstract][Full Text] [Related]
12. Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.
Yamamoto K; Ninomaru T; Okada H; Hirano K; Shimada T; Hata A
Thorac Cancer; 2024 May; 15(15):1271-1275. PubMed ID: 38623812
[TBL] [Abstract][Full Text] [Related]
13. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
14. Small cell lung cancer: Novel treatments beyond immunotherapy.
Meijer JJ; Leonetti A; Airò G; Tiseo M; Rolfo C; Giovannetti E; Vahabi M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):376-385. PubMed ID: 35568295
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapeutic Options for Small Cell Lung Cancer.
Canova S; Trevisan B; Abbate MI; Colonese F; Sala L; Baggi A; Bianchi SP; D'Agostino A; Cortinovis DL
Curr Oncol Rep; 2023 Nov; 25(11):1277-1294. PubMed ID: 37870696
[TBL] [Abstract][Full Text] [Related]
16. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.
Niu X; Chen L; Li Y; Hu Z; He F
Semin Cancer Biol; 2022 Nov; 86(Pt 3):273-285. PubMed ID: 35288298
[TBL] [Abstract][Full Text] [Related]
18. What Are the Biomarkers for Immunotherapy in SCLC?
Longo V; Catino A; Montrone M; Pizzutilo P; Annese T; Pesola F; Marech I; Cassiano S; Ribatti D; Galetta D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681779
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
20. Treatment of small cell lung cancer: recent advances.
Chu X; Han C; Su C
Curr Opin Oncol; 2022 Jan; 34(1):83-88. PubMed ID: 34698669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
